Danaher (DHR) closed at $230.11 on November 3, 2026, up 0.9% from the previous close, on volume of 2,161,058 shares (30-day average 4,354,672).
Data as of November 3, 2026.
Danaher unit Cepheid wins FDA nod for Xpert Hemorrhagic Fever Panel
Seeking Alpha News (Tue, 3-Nov 1:58 PM ET)
Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences
PRNewswire (Mon, 2-Nov 4:30 PM ET)
Danaher Reports Third Quarter 2026 Results
PRNewswire (Wed, 21-Oct 6:01 AM ET)
Danaher Collaborates with NVIDIA to Advance Autonomous Science
PRNewswire (Wed, 14-Oct 2:00 AM ET)
Danaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of Directors
PRNewswire (Mon, 12-Oct 4:25 PM ET)
Danaher Plans an AI-Powered Autonomous Lab Aiming for Up to 8x Faster Antibody Reagent Discovery
Market Chameleon (Wed, 7-Oct 4:37 AM ET)
Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab
PRNewswire (Wed, 7-Oct 7:00 AM ET)
Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer
PRNewswire (Thu, 1-Oct 7:00 AM ET)
Danaher Schedules Third Quarter 2026 Earnings Conference Call
PRNewswire (Tue, 22-Sep 4:16 PM ET)
Business Wire (Wed, 16-Sep 8:03 AM ET)
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Danaher trades on the NYSE stock market under the symbol DHR.
As of November 3, 2026, DHR stock price climbed to $230.11 with 2,161,058 million shares trading.
DHR has a beta of 0.28, meaning it tends to be less sensitive to market movements. DHR has a correlation of 0.01 to the broad based SPY ETF.
DHR has a market cap of $161.76 billion. This is considered a Large Cap stock.
Last quarter Danaher reported $7 billion in Revenue and $2.11 earnings per share. This fell short of revenue expectation by $-4 million and exceeded earnings estimates by $.19.
In the last 3 years, DHR traded as high as $281.70 and as low as $160.93.
The top ETF exchange traded funds that DHR belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
DHR has underperformed the market in the last year with a return of +7.5%, while SPY returned +11.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in DHR shares. However, DHR has outperformed the market in the last 3 month and 2 week periods, returning +18.2% and +2.5%, while SPY returned +1.2% and -1.6%, respectively. This indicates DHR has been having a stronger performance recently.
DHR support price is $223.28 and resistance is $232.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DHR shares will trade within this expected range on the day.